A phase 2 study of nivolumab combined with ibrutinib in patients with diffuse large B-cell Richter transformation of CLL
暂无分享,去创建一个
Naveen Garg | Catherine J. Wu | P. Sharma | J. Allison | H. Kantarjian | T. Kadia | G. Borthakur | N. Daver | C. Bueso-Ramos | M. Keating | S. O'brien | J. Burger | J. Khoury | N. Pemmaraju | N. Jain | S. Basu | Xuemei Wang | W. Wierda | A. Ferrajoli | B. Thakral | Erin M. Parry | A. Ayala | Jayastu Senapati | P. Thompson | M. Konopleva | W. Lopez | J. Senapati | C. Bueso‐Ramos | E. Parry | Sreyashi Basu | Padmanee Sharma
[1] C. Cheah,et al. Emerging Therapies for the Management of Richter Transformation. , 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] M. Kesavan,et al. Cellular Therapy in High-Risk Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter Syndrome , 2022, Frontiers in Oncology.
[3] Douglas B. Johnson,et al. Immune-checkpoint inhibitors: long-term implications of toxicity , 2022, Nature Reviews Clinical Oncology.
[4] A. Schuh,et al. Acalabrutinib monotherapy for treatment of chronic lymphocytic leukaemia (ACE-CL-001): analysis of the Richter transformation cohort of an open-label, single-arm, phase 1-2 study. , 2021, The Lancet. Haematology.
[5] M. Hallek,et al. Chronic lymphocytic leukemia: 2022 update on diagnostic and therapeutic procedures , 2021, American journal of hematology.
[6] I. Levy,et al. Richter Transformation in Chronic Lymphocytic Leukemia: Update in the Era of Novel Agents , 2021, Cancers.
[7] W. Wierda,et al. PIRTOBRUTINIB (LOXO‐305), A NEXT GENERATION HIGHLY SELECTIVE NON‐COVALENT BTK INHIBITOR IN PREVIOUSLY TREATED RICHTER TRANSFORMATION: RESULTS FROM THE PHASE 1/2 BRUIN STUDY , 2021, Hematological Oncology.
[8] S. Slager,et al. Distinct immune signatures in chronic lymphocytic leukemia and Richter syndrome , 2021, Blood Cancer Journal.
[9] P. Feugier,et al. Microenvironment Remodeling and Subsequent Clinical Implications in Diffuse Large B-Cell Histologic Variant of Richter Syndrome , 2020, Frontiers in Immunology.
[10] A. Nagler,et al. Safety and Efficacy of CD19-CAR T Cells in Richter's Transformation after Targeted Therapy for Chronic Lymphocytic Leukemia , 2020 .
[11] J. Byrd,et al. Clinical activity of axicabtagene ciloleucel in adult patients with Richter syndrome. , 2020, Blood advances.
[12] A. Stathis,et al. Pembrolizumab in relapsed or refractory Richter syndrome , 2020, British journal of haematology.
[13] S. Slager,et al. Clinical characteristics and outcomes of Richter transformation: experience of 204 patients from a single center , 2019, Haematologica.
[14] A. López-Guillermo,et al. Safety and activity of ibrutinib in combination with nivolumab in patients with relapsed non-Hodgkin lymphoma or chronic lymphocytic leukaemia: a phase 1/2a study. , 2019, The Lancet. Haematology.
[15] W. Faridi,et al. Significant Risk of Graft-versus-Host Disease with Exposure to Checkpoint Inhibitors before and after Allogeneic Transplantation. , 2019, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[16] A. Behdad,et al. PD‐1 is highly expressed by neoplastic B‐cells in Richter transformation , 2018, British journal of haematology.
[17] J. Byrd,et al. Use of PD‐1 (PDCD1) inhibitors for the treatment of Richter syndrome: experience at a single academic centre , 2018, British journal of haematology.
[18] T. Shanafelt,et al. PD-1 Expression in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) and Large B-cell Richter Transformation (DLBCL-RT): A Characteristic Feature of DLBCL-RT and Potential Surrogate Marker for Clonal Relatedness , 2018, The American journal of surgical pathology.
[19] D. Rossi,et al. Biology and treatment of Richter syndrome. , 2018, Blood.
[20] Jeffrey A Jones,et al. A single‐institution retrospective cohort study of first‐line R‐EPOCH chemoimmunotherapy for Richter syndrome demonstrating complex chronic lymphocytic leukaemia karyotype as an adverse prognostic factor , 2018, British journal of haematology.
[21] A. Tojo,et al. Association between GvHD and nivolumab in the FDA adverse event reporting system , 2017, Bone Marrow Transplantation.
[22] Deborah A. Bowen,et al. Pembrolizumab in patients with CLL and Richter transformation or with relapsed CLL. , 2017, Blood.
[23] R. V. Van Heertum,et al. Lugano 2014 criteria for assessing FDG-PET/CT in lymphoma: an operational approach for clinical trials , 2017, Drug design, development and therapy.
[24] R. Houot,et al. Efficacy and tolerability of nivolumab after allogeneic transplantation for relapsed Hodgkin lymphoma. , 2017, Blood.
[25] T. Kipps,et al. Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[26] Jeffrey A Jones,et al. Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre study. , 2016, The Lancet. Oncology.
[27] J. Gribben,et al. NCRI phase II study of CHOP in combination with ofatumumab in induction and maintenance in newly diagnosed Richter syndrome , 2016, British journal of haematology.
[28] M. Keating,et al. Richter transformation of CLL , 2016, Expert review of hematology.
[29] H. Döhner,et al. Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial. , 2016, Blood.
[30] S. Leprêtre,et al. Platinum and high‐dose cytarabine‐based regimens are efficient in ultra high/high‐risk chronic lymphocytic leukemia and Richter's syndrome: results of a French retrospective multicenter study , 2015, European journal of haematology.
[31] J. Gribben,et al. Mechanisms of PD-L1/PD-1-mediated CD8 T-cell dysfunction in the context of aging-related immune defects in the Eµ-TCL1 CLL mouse model. , 2015, Blood.
[32] J. Gribben,et al. PD-L1 checkpoint blockade prevents immune dysfunction and leukemia development in a mouse model of chronic lymphocytic leukemia. , 2015, Blood.
[33] Deborah A. Bowen,et al. The efficacy of ibrutinib in the treatment of Richter syndrome. , 2015, Blood.
[34] H. Kohrt,et al. Therapeutic antitumor immunity by checkpoint blockade is enhanced by ibrutinib, an inhibitor of both BTK and ITK , 2015, Proceedings of the National Academy of Sciences.
[35] H. Döhner,et al. Poor efficacy and tolerability of R‐CHOP in relapsed/refractory chronic lymphocytic leukemia and Richter transformation , 2014, American journal of hematology.
[36] J. Gribben,et al. Immunomodulation and immune reconstitution in chronic lymphocytic leukemia. , 2014, Seminars in hematology.
[37] Jeffrey A Jones,et al. Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes. , 2013, Blood.
[38] Jeffrey A Jones,et al. Phase I-II clinical trial of oxaliplatin, fludarabine, cytarabine, and rituximab therapy in aggressive relapsed/refractory chronic lymphocytic leukemia or Richter syndrome. , 2013, Clinical lymphoma, myeloma & leukemia.
[39] J. Gribben,et al. Multiple inhibitory ligands induce impaired T-cell immunologic synapse function in chronic lymphocytic leukemia that can be blocked with lenalidomide: establishing a reversible immune evasion mechanism in human cancer. , 2012, Blood.
[40] J. Byrd,et al. Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug. , 2008, The Journal of clinical investigation.
[41] Michael Hallek,et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. , 2008, Blood.
[42] K. Do,et al. Clinical outcomes and prognostic factors in patients with Richter's syndrome treated with chemotherapy or chemoimmunotherapy with or without stem-cell transplantation. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[43] R. Simon,et al. Optimal two-stage designs for phase II clinical trials. , 1989, Controlled clinical trials.
[44] B. Hoerni,et al. [Treatment of chronic lymphocytic leukemia]. , 1971, Bordeaux medical.